4528 ONO PHARMACEUTICAL CO., LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4528

TSE Prime

ONO PHARMACEUTICAL CO., LTD.

1,600.5

JPY

-5.5

(-0.34%)

Dec 23, 3:30 pm JST

10.22

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

1,588

Dec 23, 5:40 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	309,284	98,330	100,890	75,425	151.1	50	May 11, 2021	IFRS
Mar, 2022	361,361	103,195	105,025	80,519	162.2	56	May 11, 2022	IFRS
Mar, 2023	447,187	141,963	143,532	112,723	230.9	70	May 10, 2023	IFRS
Mar, 2024	502,672	159,935	163,734	127,977	266.6	80	May 9, 2024	IFRS
Mar, 2025 Guidance	485,000	82,000	81,500	58,000	123.5	80	Oct 31, 2024	IFRS
YoY	-3.5%	-48.7%	-50.2%	-54.7%	-53.7%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 9, 2019	290,000	67,000	70,000	53,000	45	IFRS
	Jan 31, 2020	290,000	71,000	73,000	55,000	45	IFRS
Results	May 12, 2020	292,420	77,491	79,696	59,704	45	IFRS
Mar, 2021	May 12, 2020	Available in future release
	Oct 29, 2020
	Feb 1, 2021
	Apr 28, 2021
Results	May 11, 2021
Mar, 2022	May 11, 2021
	May 13, 2021
	Jan 31, 2022
Results	May 11, 2022
Mar, 2023	May 11, 2022
	Oct 31, 2022
Results	May 10, 2023
Mar, 2024	May 10, 2023
	Nov 1, 2023
Results	May 9, 2024
Mar, 2025	May 9, 2024	450,000	122,000	123,000	91,000	80	IFRS
	Oct 31, 2024	485,000	82,000	81,500	58,000	80	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	127,345	+4.9	Available in future release
Mar, 2001	130,728	+2.7
Mar, 2002	133,353	+2.0
Mar, 2003	134,993	+1.2
Mar, 2004	139,383	+3.3
Mar, 2005	145,302	+4.2
Mar, 2006	148,671	+2.3
Mar, 2007	141,711	-4.7
Mar, 2008	145,897	+3.0
Mar, 2009	136,556	-6.4
Mar, 2010	135,986	-0.4
Mar, 2011	135,255	-0.5
Mar, 2012	145,778	+7.8
Mar, 2013	142,806	-2.0
Mar, 2014	143,247	+0.3
Mar, 2015	135,775	-5.2
Mar, 2016	160,284	+18.1
Mar, 2017	244,797	+52.7
Mar, 2018	261,836	+7.0
Mar, 2019	288,634	+10.2
Mar, 2020	292,420	+1.3
Mar, 2021	309,284	+5.8
Mar, 2022	361,361	+16.8
Mar, 2023	447,187	+23.8
Mar, 2024	502,672	+12.4
Mar, 2025 Guidance	485,000	-3.5	82,000	-48.7	81,500	-50.2	123.5	-53.7

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	447,187	141,963	31.8	16.13	13.90	0.55	230.9
Mar, 2024	502,672	159,935	31.8	16.68	14.25	0.56	266.6
Mar, 2025 Guidance	485,000	82,000	16.9	7.41	5.54	0.46	123.5

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	502,672	159,935	163,734	127,977	266.6
Fiscal Year	Mar, 2024	Mar, 2024	Mar, 2024	Mar, 2024	Mar, 2024

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	187,284	45,024	45,794	34,229	69.0	28	May 11, 2022	IFRS
Oct - Mar, 2022	230,486	61,693	62,513	50,384	103.2	37	May 10, 2023	IFRS
Oct - Mar, 2023	243,959	62,899	64,438	53,486	111.4	40	May 9, 2024	IFRS
Oct - Mar, 2024 Guidance	244,661	26,119	26,863	16,359	34.8	40	Oct 31, 2024	IFRS
YoY	+0.3%	-58.5%	-58.3%	-69.4%	-68.7%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	103,195	67,867	61,829	6,038	-60,237	69,112	9.35	IFRS
Mar, 2023	141,963	59,351	159,610	-100,259	-32,484	96,135	10.89	IFRS
Mar, 2024	159,935	158,737	110,660	48,077	-89,848	166,141	18.18	IFRS

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	216,701	80,270	81,019	62,339	127.7	56.4	Oct 31, 2022	IFRS
Apr - Sep, 2023	258,713	97,036	99,296	74,491	153.3	60.6	Nov 1, 2023	IFRS
Apr - Sep, 2024	240,339	55,881	54,637	41,641	88.7	67.0	Oct 31, 2024	IFRS
YoY	-7.1%	-42.4%	-45.0%	-44.1%	-42.2%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	122,319	42,320	43,360	33,317	68.2	34.6	Jan 31, 2023	IFRS
Jan - Mar, 2023	108,167	19,373	19,153	17,067	35.0	17.9	May 10, 2023	IFRS
Apr - Jun, 2023	120,016	41,348	42,378	31,818	65.2	34.5	Jul 31, 2023	IFRS
Jul - Sep, 2023	138,697	55,688	56,918	42,673	87.8	40.2	Nov 1, 2023	IFRS
Oct - Dec, 2023	131,190	47,590	47,996	36,053	74.7	36.3	Jan 31, 2024	IFRS
Jan - Mar, 2024	112,769	15,309	16,442	17,433	36.3	13.6	May 9, 2024	IFRS
Apr - Jun, 2024	117,675	30,690	33,310	24,794	52.8	26.1	Jul 31, 2024	IFRS
Jul - Sep, 2024	122,664	25,191	21,327	16,847	35.9	20.5	Oct 31, 2024	IFRS
YoY	-11.6%	-54.8%	-62.5%	-60.5%	-59.2%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	76,291	-3.2	Available in future release
Jan - Mar, 2020	67,121	+2.6
Apr - Jun, 2020	74,913	+1.3
Jul - Sep, 2020	75,561	+0.7
Oct - Dec, 2020	84,459	+10.7
Jan - Mar, 2021	74,351	+10.8
Apr - Jun, 2021	87,363	+16.6
Jul - Sep, 2021	86,714	+14.8
Oct - Dec, 2021	97,353	+15.3
Jan - Mar, 2022	89,931	+21.0
Apr - Jun, 2022	106,722	+22.2
Jul - Sep, 2022	109,979	+26.8
Oct - Dec, 2022	122,319	+25.6
Jan - Mar, 2023	108,167	+20.3
Apr - Jun, 2023	120,016	+12.5
Jul - Sep, 2023	138,697	+26.1
Oct - Dec, 2023	131,190	+7.3
Jan - Mar, 2024	112,769	+4.3
Apr - Jun, 2024	117,675	-2.0
Jul - Sep, 2024	122,664	-11.6	25,191	-54.8	21,327	-62.5	35.9	-59.1

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	138,697	55,688	56,918	42,673	87.8
Fiscal Year	Sep, 2023	Sep, 2023	Sep, 2023	Sep, 2023	Sep, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	1,343.40	88.7	739,203	655,906	644,754	0.01	May 11, 2022	IFRS
Mar, 2023	1,519.19	84.1	882,437	741,869	709,890	0.01	May 10, 2023	IFRS
Mar, 2024	1,688.43	86.8	913,668	792,961	768,183	0.01	May 9, 2024	IFRS
Apr - Sep, 2024	ー	74.8	1,046,406	782,463	792,976	0.21	Oct 31, 2024	IFRS

ONO PHARMACEUTICAL CO., LTD.(4528) Financial Results